Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
Circulation (New York, N.Y.), 2018-01, Vol.137 (4), p.338-350 [Peer Reviewed Journal]2018 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2017 American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.117.032235 ;PMID: 29133605
Full text available